Status:
UNKNOWN
TACE+RFA Versus Re-resection for Recurrent Small Hepatocellular Carcinoma
Lead Sponsor:
Sun Yat-sen University
Conditions:
Hepatocellular Carcinoma
Surgery
Eligibility:
All Genders
18-75 years
Phase:
PHASE3
Brief Summary
Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world. Partial hepatectomy is still considered as the conventional therapy for HCC. Intrahepatic recurrence of HCC after partial h...
Eligibility Criteria
Inclusion
- age 18 - 75 years;
- recurrence of HCC 12 months after initial hepatectomy;
- no other treatment received except for the initial hepatectomy;
- Single tumor≤5cm in diameter; or 2-3 lesions each ≤ 3.0 cm
- lesions visible on ultrasound and with an acceptable and safe path between the lesion and the skin as shown on ultrasound;
- no severe coagulation disorders (prothrombin activity \< 40% or a platelet count of \< 40,000 / mm3;
- Eastern Co-operative Oncology Group performance(ECOG) status 0 -1
Exclusion
- the presence of vascular invasion or extrahepatic spread on imaging;
- a Child-Pugh class C liver cirrhosis or evidence of hepatic decompensation including ascites, severe coagulation disorders (prothrombin activity \< 40% or a platelet count of \< 40,000 / mm3), esophageal or gastric variceal bleeding or hepatic encephalopathy;
- an American Society of Anesthesiologists (ASA) score ≥ 3 -
Key Trial Info
Start Date :
July 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2019
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT01833286
Start Date
July 1 2013
End Date
July 1 2019
Last Update
April 16 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China, 510060